Advertisement

International Journal of Clinical Pharmacy

, Volume 39, Issue 2, pp 354–363 | Cite as

Documentation of pharmaceutical care: development of an intervention oriented classification system

  • Karen A. MaesEmail author
  • Sophia Bruch
  • Kurt E. Hersberger
  • Markus L. Lampert
Research Article

Abstract

Background A standardised classification system of pharmaceutical interventions (PI) is in use in several Swiss hospitals, whereas none exists for community pharmacies to date. To promote information exchange between both settings, a compatible structure of the classification system is needed. Objective To develop an intervention oriented classification system for community pharmacies named PharmDISC based on the hospital system; to test it on interrater reliability, appropriateness, interpretability, and face and content validity; to assess pharmacists’ opinions. Setting Seventy-seven Swiss community pharmacies. Method Based on previous studies, a modified classification system was developed. Fifth-year pharmacy students (n = 77) received a two-hour training and classified three model PIs with which Fleiss-Kappa coefficients K were calculated to determine interrater reliability. In the community pharmacies, each student consecutively collected ten prescriptions that required a PI. A focus group interview was conducted with pharmacists (n = 9). The anonymised transcript was analysed using thematic analysis. Main outcome measure Number of classified PIs, interrater reliability, pharmacists’ opinion/suggestions. Results The classification system includes 5 categories and 52 subcategories. Most of the 725 PIs (94.6%) were completely classified. The PharmDISC system reached an overall substantial user agreement (K = 0.61). Despite some points for optimisation, the pharmacists were satisfied with the PharmDISC system. They recognised the importance of PI documentation and believed that this may allow traceability, facilitate communication within the team and other healthcare professionals, and increase quality of care. Conclusion The PharmDISC system was valid and reached substantial interrater reliability. Refinement based on the pharmacists’ suggestions resulted in a final version to be tested in an observational study with community pharmacists.

Keywords

Classification system Community pharmacy practice Drug-related problem Mixed method Pharmaceutical care Pharmaceutical intervention 

Notes

Acknowledgements

We thank the participating fifth-year pharmacy students and their community pharmacies offering internship for collecting prescriptions and documenting the cases. The authors thank the members of the focus group (Dr. Patrick Eichenberger, Dr. Patrick Imfeld, Andrea Studer, Dr. Fabienne Böni, Pascale Prétot, Renate Allemann, Eva Franz, Dr. Jérôme Berger, Sara Zehnder) who contributed to our findings. We thank Dr. Roland Preston for proof-reading.

Funding

No grants from any external funding body were received to conduct this study.

Conflicts of interest

None.

Supplementary material

11096_2017_442_MOESM1_ESM.docx (197 kb)
Supplementary material 1 (DOCX 197 kb)

References

  1. 1.
    Pharmaceutical Care Network Europe: Definition of drug-related problem. http://www.pcne.org/working-groups/2/drug-related-problems. Accessed 20 Jan 2017.
  2. 2.
    Nicolas A, Eickhoff C, Griese N, Schulz M. Drug-related problems in prescribed medicines in Germany at the time of dispensing. Int J Clin Pharm. 2013;35(3):476–82.CrossRefPubMedGoogle Scholar
  3. 3.
    Eichenberger PM, Lampert ML, Kahmann IV, van Mil JW, Hersberger KE. Classification of drug-related problems with new prescriptions using a modified PCNE classification system. Pharm World Sci. 2010;32(3):362–72.CrossRefPubMedGoogle Scholar
  4. 4.
    Hersberger KE, Botomino A, Sarkar R, Tschudi P, Bucher HC, Briel M. Prescribed medications and pharmacy interventions for acute respiratory tract infections in Swiss primary care. J Clin Pharm Ther. 2009;34(4):387–95.CrossRefPubMedGoogle Scholar
  5. 5.
    Maes KA, Tremp RM, Hersberger KE, Lampert ML. Demonstrating the clinical pharmacist’s activity: validation of an intervention oriented classification system. Int J Clin Pharm. 2015;37(6):1162–71.CrossRefPubMedGoogle Scholar
  6. 6.
    American College of Clinical Pharmacy. The definition of clinical pharmacy. Pharmacotherapy. 2008;28(6):816–7.Google Scholar
  7. 7.
    Hammerlein A, Griese N, Schulz M. Survey of drug-related problems identified by community pharmacies. Ann Pharmacother. 2007;41(11):1825–32.CrossRefPubMedGoogle Scholar
  8. 8.
    Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD. Drug-related problems: their structure and function. Ann Pharmacother. 1990;24(11):1093–7.Google Scholar
  9. 9.
    Westerlund LO, Handl WH, Marklund BR, Allebeck P. Pharmacy practitioners’ views on computerized documentation of drug-related problems. Ann Pharmacother. 2003;37(3):354–60.CrossRefPubMedGoogle Scholar
  10. 10.
    van Mil JW, Westerlund LO, Hersberger KE, Schaefer MA. Drug-related problem classification systems. Ann Pharmacother. 2004;38(5):859–67.CrossRefPubMedGoogle Scholar
  11. 11.
    Williams M, Peterson GM, Tenni PC, Bindoff IK, Stafford AC. DOCUMENT: a system for classifying drug-related problems in community pharmacy. Int J Clin Pharm. 2012;34(1):43–52.CrossRefPubMedGoogle Scholar
  12. 12.
    Schaefer M. Discussing basic principles for a coding system of drug-related problems: the case of PI-Doc. Pharm World Sci. 2002;24(4):120–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Bjorkman IK, Sanner MA, Bernsten CB. Comparing 4 classification systems for drug-related problems: processes and functions. Res Soc Adm Pharm. 2008;4(4):320–31.CrossRefGoogle Scholar
  14. 14.
    Basger BJ, Moles RJ, Chen TF. Application of drug-related problem (DRP) classification systems: a review of the literature. Eur J Clin Pharmacol. 2014;70(7):799–815.CrossRefPubMedGoogle Scholar
  15. 15.
    Basger BJ, Moles RJ, Chen TF. Development of an aggregated system for classifying causes of drug-related problems. Ann Pharmacother. 2015;49(4):405–18.CrossRefPubMedGoogle Scholar
  16. 16.
    Pharmaceutical Care Network Europe, Classification for Drug Related Problems V6.2. http://www.pcne.org/upload/files/11_PCNE_classification_V6-2.pdf. Accessed 20 Jan 2017.
  17. 17.
    Comité de Consenso. Third Consensus of Granada on Drug Related Problems (DRP) and Negative Outcomes associated with Medication (NOM), Spanish. Ars Pharm. 2007;48(1):5–17.Google Scholar
  18. 18.
    Krahenbuhl JM, Kremer B, Guignard B, Bugnon O. Practical evaluation of the drug-related problem management process in Swiss community pharmacies. Pharm World Sci. 2008;30(6):777–86.CrossRefPubMedGoogle Scholar
  19. 19.
    Hohmann C, Eickhoff C, Klotz JM, Schulz M, Radziwill R. Development of a classification system for drug-related problems in the hospital setting (APS-Doc) and assessment of the inter-rater reliability. J Clin Pharm Ther. 2012;37(3):276–81.CrossRefPubMedGoogle Scholar
  20. 20.
    Allenet B, Bedouch P, Rose FX, Escofier L, Roubille R, Charpiat B, et al. Validation of an instrument for the documentation of clinical pharmacists’ interventions. Pharm World Sci. 2006;28(4):181–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Williams M, Peterson G, Tenni P, Bindoff I, Stafford A. DOCUMENT: a system for classifying drug-related problems in community pharmacy. Int J Clin Pharm. 2012;34(1):43–52.CrossRefPubMedGoogle Scholar
  22. 22.
    Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ. 2008;337:a1655.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Ganso M, Areschin S, Lange P, Emser A, Rössler J, Krämer I. Verlässlichkeit eines Klassifikationssystems für pharmazeutische Interventionen. Krankenhauspharmazie. 2007;28(7):273–83.Google Scholar
  24. 24.
    King J. Resource page: generalized Kappa and other indices of interrater reliability. http://www.ccitonline.org/jking/homepage/interrater.html. Accessed 20 Jan 2017.
  25. 25.
    Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74.CrossRefPubMedGoogle Scholar
  26. 26.
    Kaufmann CP, Stampfli D, Hersberger KE, Lampert ML. Determination of risk factors for drug-related problems: a multidisciplinary triangulation process. BMJ Open. 2015;5(3):e006376.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–57.CrossRefPubMedGoogle Scholar
  28. 28.
    Ryan C, Cadogan C, Hughes C. Mixed methods research in pharmacy practice. In: Babar ZUD, editor. Pharmacy practice research methods. Basel: Springer; 2015. p. 107–21.Google Scholar
  29. 29.
    Driscoll DL, Appiah-Yeboah A, Salib P, Rupert DJ. Merging qualitative and quantitative data in mixed methods research: how to and why not. Ecol Environ Anthropol. 2007;3:19–27.Google Scholar
  30. 30.
    Brock KA, Casper KA, Green TR, Pedersen CA. Documentation of patient care services in a community pharmacy setting. J Am Pharm Assoc. 2006;46(3):378–84.CrossRefGoogle Scholar
  31. 31.
    Westerlund T, AlmarsdÓTtir AB, Melander A. Drug-related problems and pharmacy interventions in community practice. Int J Pharm Pract. 1999;7(1):40–50.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing 2017

Authors and Affiliations

  • Karen A. Maes
    • 1
    Email author
  • Sophia Bruch
    • 1
  • Kurt E. Hersberger
    • 1
  • Markus L. Lampert
    • 1
    • 2
  1. 1.Pharmaceutical Care Research Group, Department of Pharmaceutical SciencesUniversity of BaselBaselSwitzerland
  2. 2.Institute of Hospital PharmacySolothurner SpitälerOltenSwitzerland

Personalised recommendations